NCT07143968View on ClinicalTrials.gov

A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

June 30, 2027

Study Completion Date

January 31, 2028

Conditions
MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseHIV (Human Immunodeficiency Virus)
Interventions
DRUG

Resmetirom

Resmetirom - 80mg or 100mg based on participant weight

DRUG

Placebo Control

Placebo - an identical looking tablet with no medicinal properties

All Listed Sponsors
lead

Naga P. Chalasani

OTHER